Advertisement
Screener

WINDTREE THERAPEUTICS INC /DE/ (WINT) Deferred Income Tax Expense (Benefit)

WINDTREE THERAPEUTICS INC /DE/ Deferred Income Tax Expense (Benefit)

WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Deferred Income Tax Expense (Benefit) of -$3.23 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-19.

Financial Statements › Cash Flow › Operating Activities

us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2025-11-19

  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for the quarter ending 2024-12-31 was -$210.00K.
  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for the quarter ending 2022-12-31 was -$1.37M.
  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for the quarter ending 2022-09-30 was $0.00.
  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for the quarter ending 2021-12-31 was -$1.66M.
  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for fiscal 2024 was -$210.00K.
  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for fiscal 2023 was $0.00.
  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for fiscal 2022 was -$1.37M.
  • WINDTREE THERAPEUTICS INC /DE/ deferred income tax expense (benefit) for fiscal 2021 was -$9.99M.
Period endDeferred Income Tax Expense (Benefit) 3 monthDeferred Income Tax Expense (Benefit) 6 monthDeferred Income Tax Expense (Benefit) 9 monthDeferred Income Tax Expense (Benefit) 12 month
2025-09-30-$3.23M
10-Q · filed 2025-11-19
2024-12-31-$210.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
-$210.00K
10-K · filed 2025-04-15
2024-09-30$0.00
10-Q · filed 2025-11-19
2023-12-31$0.00
10-K · filed 2025-04-15
2022-12-31-$1.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16
-$1.37M
derived: sum of 2 quarters · filed 2024-04-16
-$1.37M
10-K · filed 2024-04-16
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$0.00
10-Q · filed 2022-11-14
2022-06-30$0.00
10-Q · filed 2022-08-11
2021-12-31-$1.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
-$1.66M
derived: sum of 2 quarters · filed 2023-03-31
-$9.96M
derived: sum of 3 quarters · filed 2023-03-31
-$9.99M
10-K · filed 2023-03-31
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$8.30M
derived: sum of 2 quarters · filed 2022-11-14
-$8.33M
10-Q · filed 2022-11-14
2021-06-30-$8.30M
10-Q · filed 2022-08-11
-$8.33M
10-Q · filed 2022-08-11
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$0.00
derived: sum of 2 quarters · filed 2022-03-31
$0.00
10-K · filed 2022-03-31
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
$0.00
10-Q · filed 2021-11-10
2020-06-30$0.00
10-Q · filed 2021-08-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
CURIS INC (CRIS)United States$0.002B-0.05
Silexion Therapeutics Corp (SLXN)$0.001B
AIM ImmunoTech Inc. (AIM)United States$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70